FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period endedMarch 31, 2013
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 1-10986
MISONIX, INC.
(Exact name of registrant as specified in its charter)
| New York | 11-2148932 | |
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) | |
| 1938 New Highway, Farmingdale, NY | 11735 | |
| (Address of principal executive offices) | (Zip Code) |
(631) 694-9555
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesx No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yesx No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer ¨ | Accelerated filer ¨ | Non-accelerated filer ¨ | Smaller reporting company x |
| (Do not check if a smaller reporting company) | |||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨Nox
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
| Outstanding at | ||||
| Class of Common Stock | May 8, 2013 | |||
| Common Stock, $.01 par value | 7,091,986 | |||
MISONIX, INC.
INDEX
| Page | |
| Part I - FINANCIAL INFORMATION | |
| Item 1. Financial Statements: | |
| Consolidated Balance Sheets as of March 31, 2013 (Unaudited) and June 30, 2012 | 3 |
| Consolidated Statements of Operations for the Nine months ended March 31, 2013 and 2012 (Unaudited) | 4 |
| Consolidated Statements of Operations for the Three months ended March 31, 2013 and 2012 (Unaudited) | 5 |
| Consolidated Statement of Stockholders’ Equity for the Nine months ended March 31, 2013 (Unaudited) | 6 |
| Consolidated Statements of Cash Flows for the Nine months ended March 31, 2013 and 2012 (Unaudited) | 7 |
| Notes to Consolidated Financial Statements (Unaudited) | 8 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 23 |
| Item 4. Controls and Procedures | 24 |
| Part II - OTHER INFORMATION | |
| Item 1A. Risk Factors | 25 |
| Item 6. Exhibits | 25 |
| Signatures | 26 |
| EX-31.1 | |
| EX-31.2 | |
| EX-32.1 | |
| EX-32.2 |
| 2 |
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
MISONIX, INC. and Subsidiaries
Consolidated Balance Sheets
| March 31, | June 30, | |||||||
| 2013 | 2012 | |||||||
| (Unaudited) | (derived from audited financial statements) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,091,564 | $ | 6,273,015 | ||||
| Accounts receivable, less allowance for doubtful accounts of $199,641 and $155,739, respectively | 2,788,281 | 3,158,084 | ||||||
| Inventories, net | 4,448,400 | 4,380,841 | ||||||
| Prepaid expenses and other current assets | 328,219 | 306,691 | ||||||
| Note receivable | - | 198,117 | ||||||
| Total current assets | 13,656,464 | 14,316,748 | ||||||
| Property, plant and equipment, net | 1,172,781 | 891,822 | ||||||
| Goodwill | 1,701,094 | 1,701,094 | ||||||
| Intangible and other assets | 1,193,205 | 1,403,173 | ||||||
| Total assets | $ | 17,723,544 | $ | 18,312,837 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,367,586 | $ | 1,507,695 | ||||
| Accrued expenses and other current liabilities | 1,203,282 | 1,074,932 | ||||||
| Total current liabilities | 2,570,868 | 2,582,627 | ||||||
| Deferred lease liability | 23,607 | 22,996 | ||||||
| Deferred income | 83,987 | 117,147 | ||||||
| Total liabilities | 2,678,462 | 2,722,770 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock, $.01 par value-shares authorized 20,000,000,7,169,046and 7,082,920 | ||||||||
| shares issued and7,091,486 and 7,005,360 shares outstanding, respectively | 71,690 | 70,829 | ||||||
| Additional paid-in capital | 26,724,370 | 26,132,951 | ||||||
| Accumulated deficit | (11,339,985 | ) | (10,202,720 | ) | ||||
| Treasury stock, at cost, 77,560 shares | (410,993 | ) | (410,993 | ) | ||||
| Total stockholders' equity | 15,045,082 | 15,590,067 | ||||||
| Total liabilities and stockholders' equity | $ | 17,723,544 | $ | 18,312,837 | ||||
See Accompanying Notes to Consolidated Financial Statements.
| 3 |
MISONIX, INC. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
| For the nine months ended | ||||||||
| March 31, | ||||||||
| 2013 | 2012 | |||||||
| Net sales | $ | 11,068,243 | $ | 10,377,480 | ||||
| Cost of goods sold | 4,953,193 | 4,226,193 | ||||||
| Gross profit | 6,115,050 | 6,151,287 | ||||||
| Operating expenses: | ||||||||
| Selling expenses | 4,768,867 | 3,620,079 | ||||||
| General and administrative expenses | 3,290,671 | 3,274,234 | ||||||
| Research and development expenses | 1,143,289 | 946,984 | ||||||
| Total operating expenses | 9,202,827 | 7,841,297 | ||||||
| Loss from operations | (3,087,777 | ) | (1,690,010 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 56 | 406 | ||||||
| Interest expense | - | (435 | ) | |||||
| Royalty income and license fees | 1,770,217 | 462,301 | ||||||
| Royalty expense/fee recovery | (5,295 | ) | 112,617 | |||||
| Other | (51,563 | ) | (25,468 | ) | ||||
| Total other income | 1,713,415 | 549,421 | ||||||
| Loss from continuing operations before income taxes | (1,374,362 | ) | (1,140,589 | ) | ||||
| Income tax benefit | (55,297 | ) | (288,135 | ) | ||||
| Net loss from continuing operations | (1,319,065 | ) | (852,454 | ) | ||||
| Discontinued operations: | ||||||||
| Income/(loss) from discontinued operations net of tax expense of $1,619 and a tax benefit of $181,587, respectively | 13,149 | (369,424 | ) | |||||
| Gain from sale of discontinued operations net of tax expense of $81,349 and $562,024, respectively | 168,651 | 1,143,390 | ||||||
| Net income from discontinued operations | 181,800 | 773,966 | ||||||
| Net loss | $ | (1,137,265 | ) | $ | (78,488 | ) | ||
| Net loss per share from continuing operations - Basic | $ | (0.19 | ) | $ | (0.12 | ) | ||
| Net income per share from discontinued operations - Basic | 0.03 | 0.11 | ||||||
| Net loss per share - Basic | $ | (0.16 | ) | $ | (0.01 | ) | ||
| Net loss per share from continuing operations - Diluted | $ | (0.19 | ) | $ | (0.12 | ) | ||
| Net income per share from discontinued operations - Diluted | 0.03 | 0.11 | ||||||
| Net loss per share - Diluted | $ | (0.16 | ) | $ | (0.01 | ) | ||
| Weighted average shares - Basic | 7,028,790 | 7,001,381 | ||||||
| Weighted average shares - Diluted | 7,028,790 | 7,001,381 | ||||||
See Accompanying Notes to Consolidated Financial Statements.
| 4 |
MISONIX, INC. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
| For the three months ended | ||||||||
| March 31, | ||||||||
| 2013 | 2012 | |||||||
| Net sales | $ | 3,023,487 | $ | 3,609,746 | ||||
| Cost of goods sold | 1,482,329 | 1,491,225 | ||||||
| Gross profit | 1,541,158 | 2,118,521 | ||||||
| Operating expenses: | ||||||||
| Selling expenses | 1,764,718 | 1,245,782 | ||||||
| General and administrative expenses | 1,155,613 | 1,024,029 | ||||||
| Research and development expenses | 379,901 | 333,308 | ||||||
| Total operating expenses | 3,300,232 | 2,603,119 | ||||||
| Loss from operations | (1,759,074 | ) | (484,598 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 18 | 248 | ||||||
| Interest expense | - | (72 | ) | |||||
| Royalty income and license fees | 1,025,153 | 135,794 | ||||||
| Royalty expense/fee recovery | (182 | ) | (8,659 | ) | ||||
| Other | (25,378 | ) | (4,989 | ) | ||||
| Total other income | 999,611 | 122,322 | ||||||
| Loss from continuing operations before income taxes | (759,463 | ) | (362,276 | ) | ||||
| Income tax benefit | (59,126 | ) | (85,862 | ) | ||||
| Net loss from continuing operations | (700,337 | ) | (276,414 | ) | ||||
| Discontinued operations: | ||||||||
| Income/(loss) from discontinued operations net of tax expense of $1,619 and a tax benefit of $51,070, respectively | 3,356 | (163,243 | ) | |||||
| Gain from sale of discontinued operations net of tax expense of $81,349 and $29,756, respectively | 168,651 | 225,032 | ||||||
| Net income from discontinued operations | 172,007 | 61,789 | ||||||
| Net loss | $ | (528,330 | ) | $ | (214,625 | ) | ||
| Net loss per share from continuing operations - Basic | $ | (0.10 | ) | $ | (0.04 | ) | ||
| Net income per share from discontinued operations - Basic | 0.02 | 0.01 | ||||||
| Net loss per share - Basic | $ | (0.08 | ) | $ | (0.03 | ) | ||
| Net loss per share from continuing operations - Diluted | $ | (0.10 | ) | $ | (0.04 | ) | ||
| Net income per share from discontinued operations - Diluted | 0.02 | 0.01 | ||||||
| Net loss per share - Diluted | $ | (0.08 | ) | $ | (0.03 | ) | ||
| Weighted average shares - Basic | 7,060,965 | 7,001,404 | ||||||
| Weighted average shares - Diluted | 7,060,965 | 7,001,404 | ||||||
See Accompanying Notes to Consolidated Financial Statements.
| 5 |
MISONIX, INC. and Subsidiaries
Consolidated Statement of Stockholders’ Equity
(Unaudited)
For the nine months ended March 31, 2013
| Common Stock, | ||||||||||||||||||||||||||||
| $.01 Par Value | Treasury Stock | Additional | Total | |||||||||||||||||||||||||
| Number | Number | paid-in | Accumulated | stockholders' | ||||||||||||||||||||||||
| of shares | Amount | of shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| Balance, June 30, 2012 | 7,082,920 | $ | 70,829 | (77,560 | ) | $ | (410,993 | ) | $ | 26,132,951 | $ | (10,202,720 | ) | $ | 15,590,067 | |||||||||||||
| Net loss/comprehensive loss | - | - | - | - | - | (1,137,265 | ) | (1,137,265 | ) | |||||||||||||||||||
| Proceeds from excercise of stock options | 86,126 | 861 | - | - | 234,967 | - | 235,828 | |||||||||||||||||||||
| Stock-based compensation | - | - | - | - | 356,452 | - | 356,452 | |||||||||||||||||||||
| Balance, March 31, 2013 | 7,169,046 | $ | 71,690 | (77,560 | ) | $ | (410,993 | ) | $ | 26,724,370 | $ | (11,339,985 | ) | $ | 15,045,082 | |||||||||||||
See Accompanying Notes to Consolidated Financial Statements.
| 6 |
MISONIX, INC. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
| For the nine months ended | ||||||||
| March 31, | ||||||||
| 2013 | 2012 | |||||||
| Operating activities | ||||||||
| Net loss from continuing operations | $ | (1,319,065 | ) | $ | (852,454 | ) | ||
| Adjustments to reconcile net loss to net cash provided by/(used) in continuing operating activities: | ||||||||
| Depreciation and amortization and other non-cash items | 572,138 | 524,362 | ||||||
| Bad debt expense (recovery) | 43,902 | 25,000 | ||||||
| Stock-based compensation | 356,452 | 256,193 | ||||||
| Deferred income | (21,164 | ) | (80,322 | ) | ||||
| Deferred lease liability | 611 | 6,714 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 325,901 | 59,816 | ||||||
| Inventories | 130,558 | (934,579 | ) | |||||
| Prepaid expenses and other assets | 65,657 | 160,679 | ||||||
| Accounts payable, accrued expenses and other non-cash items | (23,755 | ) | (789,186 | ) | ||||
| Net cash provided by/(used in) operating activities | 131,235 | (1,623,777 | ) | |||||
| �� | ||||||||
| Investing activities | ||||||||
| Acquisition of property, plant and equipment | (677,135 | ) | (397,391 | ) | ||||
| Payments for assets acquisition | - | (61,698 | ) | |||||
| Additional patents | (53,179 | ) | - | |||||
| Net cash (used in) investing activities | (730,314 | ) | (718,849 | ) | ||||
| Financing activities | ||||||||
| Principal payments on capital lease obligations | - | (11,608 | ) | |||||
| Proceeds from sale of treasury stock | - | 504 | ||||||
| Proceeds from excercise of stock options | 235,828 | - | ||||||
| Net cash provided by/(used in) financing activities | 235,828 | (11,104 | ) | |||||
| Cash flows from discontinued operations | ||||||||
| Net cash provided by/(used) in operating activities | 13,149 | (321,153 | ) | |||||
| Net cash provided by investing activities | 168,651 | 1,724,818 | ||||||
| Net cash provided by discontinued operations | 181,800 | 1,403,665 | ||||||
| Net decrease in cash and cash equivalents | (181,451 | ) | (950,065 | ) | ||||
| Cash and cash equivalents at beginning of period | 6,273,015 | 6,881,093 | ||||||
| Cash and cash equivalents at end of period | $ | 6,091,564 | $ | 5,931,028 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for: | ||||||||
| Interest | $ | - | $ | 435 | ||||
| Income taxes | $ | 22,270 | $ | 20,656 | ||||
See Accompanying Notes to Consolidated Financial Statements.
| 7 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
1.Basis of Presentation
The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the year ended June 30, 2012 (“2012 Annual Report”) of MISONIX, INC. (“Misonix” or the “ Company”). A summary of the Company’s significant accounting policies is identified in Note 1 of the notes to the consolidated financial statements included in the Company’s 2012 Annual Report. There have been no changes in the Company’s significant accounting policies subsequent to June 30, 2012.
The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X pursuant to the requirements of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the interim periods are not necessarily indicative of the results of operations for the entire year.
The consolidated financial statements of the Company include the accounts of Misonix and its 100% owned subsidiaries, Fibra-Sonics (NY) Inc. and Hearing Innovations, Inc. All significant intercompany balances and transactions have been eliminated.
Organization and Business
Misonix is a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications.
The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made primarily through distributors. Sales made in the United States are made primarily through representative agents. The following is an analysis of net sales from continuing operations by geographic region:
| Three months ended March 31, | Nine months ended March 31, | |||||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||||
| United States | $ | 1,566,912 | $ | 1,940,250 | United States | $ | 5,652,072 | $ | 5,690,301 | |||||||||
| Australia | 39,700 | 84,244 | Australia | 321,374 | 165,070 | |||||||||||||
| Europe | 579,509 | 445,504 | Europe | 2,299,808 | 1,919,508 | |||||||||||||
| Asia | 309,696 | 569,302 | Asia | 1,093,479 | 1,052,988 | |||||||||||||
| Canada and Mexico | 180,756 | 55,375 | Canada and Mexico | 436,738 | 346,316 | |||||||||||||
| South America | 171,992 | 174,886 | South America | 578,380 | 454,625 | |||||||||||||
| South Africa | 51,162 | 111,535 | South Africa | 363,429 | 253,250 | |||||||||||||
| Middle East | 123,760 | 228,650 | Middle East | 322,963 | 495,422 | |||||||||||||
| $ | 3,023,487 | $ | 3,609,746 | $ | 11,068,243 | $ | 10,377,480 | |||||||||||
On December 12, 2012, the Company announced the termination of its distribution agreement with Aesculap, Inc. (“Aesculap”), for the Misonix BoneScalpel™ Ultrasonic Bone Cutting System as of January 1, 2013. Since January 2011, Aesculap has been a non-exclusive, private label distributor of the BoneScalpel in the United States, for clinical applications in spine surgery and cranial surgery. Under the non-exclusive distribution agreement, Aesculap retains the right to sell BoneScalpel disposables to certain, limited hospital accounts, post termination, which are covered by binding supply agreements for varying periods of time, but not to exceed 3 years. The termination requires Misonix to purchase all hardware inventory in Aesculap’s possession, which will be recorded as either fixed assets or inventory.
| 8 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
Discontinued Operations
Laboratory and Forensic Safety Products Business
On October 19, 2011, Misonix sold its Laboratory and Forensic Safety Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. (“Mystaire”) for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The Laboratory and Forensic Safety Products business manufactured and marketed ductless fume, laminar airflow and polymerase chain reaction workstations both domestically and internationally with revenues for fiscal 2011 of approximately $2.1 million.
In accordance with the Asset Purchase Agreement with Mystaire, Misonix retained, among other items, the existing accounts receivable, inventory, accounts payable and accrued expenses of the Laboratory and Forensic Safety Products business. After considering the proceeds received of $1,500,000 in cash, professional fees of $25,000 in connection with the sale and the net book value of the assets sold of $24,000, which was comprised primarily of property and equipment, Misonix reported a gain on sale of $1,451,000 and recorded income taxes of $242,000 on the gain during the fiscal year ended June 30, 2012. The earn-out will not be factored into the gain on sale until it is earned by Misonix. As of March 31, 2013 no earnout has been recorded
In accordance with the terms of the Transition and Manufacturing Services Agreement with Mystaire, which was entered into as part of the sale, Misonix continued for a period of six weeks to manufacture and deliver products for orders received prior to the closing date as well as to provide product to Mystaire as transition inventory, which transition period was completed on November 30, 2011.
| 9 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
The results of operations of the Laboratory and Forensic Safety Products business have been presented as discontinued operations for all periods presented as Misonix does not have any significant cash flow or continuing involvement in this business. Following the sale of the Laboratory and Forensic Safety Products business, the Company operates in one reportable segment, Medical Devices.
Labcaire Systems
On August 4, 2009, the Company sold its Labcaire Systems, Ltd. (“Labcaire”) subsidiary to PuriCore International Limited (“PuriCore Limited”) for a total purchase price of up to $5.6 million. The Company received $3.6 million at closing and a promissory note in the principal amount of $1 million. The Company was also to receive a commission paid on sales for the period commencing on the date of closing and ending on December 31, 2013 of 8% of the pass through Automated Endoscope Reprocessing (“AER”) and Drying Cabinet products, and 5% of license fees from any chemical licenses marketed by Labcaire directly associated with sale of AERs, specifically for the disinfection of the endoscope. The aggregate commission payable to the Company was also to be subject to a maximum payment of $1,000,000.
In January 2011, PuriCore Limited initiated a lawsuit against the Company in the High Court of Justice, Queens Bench Division, Commercial Court, Royal Courts of Justice, London, England (Claim No. 2011-42) (the “Lawsuit”). In the Lawsuit, PuriCore Limited claimed damages from the Company in respect of breach of warranties contained in the Stock Purchase Agreement, dated August 4, 2009 (the “SPA”), pursuant to which the Company sold Labcaire to PuriCore Limited. PuriCore Limited claimed damages of £2,167,000 or approximately $3,600,000, plus interest and its legal costs. The Company denied the allegations contained in the Lawsuit.
On July 19, 2011, PuriCore Limited and the Company reached an agreement to settle the Lawsuit (the “Settlement”). The Settlement provides that the Company (i) forgive in full PuriCore Limited and PuriCore plc’s obligation under the SPA to pay up to $1,000,000 of the previously unrecorded, contingent commissions (as described above); (ii) pay PuriCore, Inc. (“PuriCore”), an affiliate of PuriCore Limited, $650,000 towards PuriCore Limited’s legal costs which had been accrued for as of June 30, 2011 and (iii) enter into a Product License and Distribution Agreement, dated as of July 19, 2011, with PuriCore (the “Distribution Agreement”).
Pursuant to the Distribution Agreement, the Company has been granted the right to distribute PuriCore’s Vashe® solution products in the United States, on a private label basis called the Misonix Soma product, as an antibacterial, antimicrobial irrigating solution for the treatment of human wound care in conjunction with therapeutic ultrasonic procedures (the “Field”). PuriCore has agreed, subject to modification, not to sell the products that are the subject of the Distribution Agreement (the “Licensed Products”) to any other therapeutic ultrasound company for distribution in the Field in the United States (“Exclusivity”). The Company has agreed not to sell or distribute in the United States in the Field any irrigating solution that has anti-microbial properties other than the Licensed Products so long as the Company has Exclusivity.
The Distribution Agreement is for a three (3) year term with automatic renewals for successive two (2) year periods; provided that the Company and PuriCore have agreed upon sales volume targets for each renewal period (such volume targets not to increase by more than ten (10%) percent year over year unless otherwise agreed) and provided that the cost terms shall be no less favorable than the twelve (12) months leading up to the start of such renewal period. In no event will the Distribution Agreement survive beyond the expiration or invalidation of all of PuriCore’s patents.
During the initial three year term of the Distribution Agreement, the Company is obligated to either purchase or pay a minimum of $2,000,000 in gross margin value to PuriCore for the Licensed Products (the “Minimum Payment”). The Minimum Payment is subject to downward adjustment and elimination in the event that (i) PuriCore chooses to eliminate Exclusivity, (ii) the Company’s right to manufacture the Licensed Products under certain conditions has been triggered but the Company is unable to manufacture the Licensed Products or to have the Licensed Products manufactured for it by third parties or (iii) the U.S. Food and Drug Administration has made a final determination that prohibits the sale of the licensed products for use in the Field. As of March 31, 2013, Misonix incurred approximately $871,250 towards the minimum payment, leaving a minimum payment balance of $1,128,750; a payable of $251,383 has been accrued but not paid. The Company is currently in discussions with Puricore to terminate the Distribution Agreement as it believes that the products subject to the Distribution Agreement are non-conforming. No assurances can be given that the Company will be successful in its attempt to terminate the Distribution Agreement. At the start of fiscal 2013, the value of the note was $298,117. During fiscal 2013, Misonix purchased sufficient Licensed Products from Puricore to satisfy the remaining balance due under the note.
The Company has the right to manufacture the Licensed Products if PuriCore is unable to meet certain performance standards and will pay PuriCore a royalty after the $2,000,000 in gross margin value requirement has been satisfied if the Company is then manufacturing the Licensed Products.
During a renewal period, PuriCore may terminate the Distribution Agreement (i) if the Company fails to purchase the agreed upon volume target for such renewal period and does not cure such failure in accordance with the Distribution Agreement or (ii) upon twelve (12) months’ notice.
| 10 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
High Intensity Focused Ultrasound Technology
In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to USHIFU LLC (“USHIFU”), Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received by USHIFU related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to the $5.8 million. Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Total payments through March 31, 2013 were $504,788. Payments received during the fiscal quarter ended March 31, 2013, totaled $250,000.
Results of Discontinued Operations
| For the three months ended | For the nine months ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenues | $ | 4,975 | $ | 28,588 | $ | 14,925 | $ | 1,455,791 | ||||||||
| Income/(loss) from discontinued operations, before tax | $ | 4,975 | $ | (214,313 | ) | $ | 14,768 | $ | (551,011 | ) | ||||||
| Gain on sale of discontinued operations | 250,000 | 254,788 | 250,000 | 1,705,414 | ||||||||||||
| Income tax (expense)/benefit | (82,968 | ) | 21,314 | (82,968 | ) | (380,437 | ) | |||||||||
| Net income from discontinued operations net of tax | $ | 172,007 | $ | 61,789 | $ | 181,800 | $ | 773,966 | ||||||||
Accounts Receivable
Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.
Reclassifications
Certain prior period amounts in the accompanying financial statements and related notes have been reclassified to conform to the current period’s presentation.
2.Net Income (Loss) Per Share of Common Stock
Basic net income (loss) per common share (“basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted net loss per common share (“diluted EPS”) is computed by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents outstanding (principally outstanding common stock options) for the period.
| 11 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:
| For the nine months ended | For the three months ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Basic shares | 7,028,790 | 7,001,381 | 7,060,965 | 7,001,404 | ||||||||||||
| Dilutive effect of stock options | - | - | - | - | ||||||||||||
| Diluted shares | 7,028,790 | 7,001,381 | 7,060,965 | 7,001,404 | ||||||||||||
Diluted EPS for the nine months and three months ended March 31, 2013 and March 31, 2012 presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-diliutive. For this reason, excluded from the calculation of diluted EPS are outstanding options to purchase 1,862,079 and 1,824,680 shares of common stock for the nine and three months ended March 31, 2013 and 2012, respectively.
3.Comprehensive Income/(Loss)
Total comprehensive loss, which includes results of discontinued operations, was $1,137,265 and $528,330 for nine months and three months ended March 31, 2013 and a loss of $78,488 and $214,625 for the nine and three months ended March 31, 2012, respectively. There are no components of comprehensive income/(loss) other than net income/(loss) for all periods presented.
| 12 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
4.Stock-Based Compensation
Stock options are granted with exercise prices not less than the fair market value of our common stock at the time of the grant, with an exercise term (as determined by the committee administering the applicable option plan (the “Committee”)) not to exceed 10 years. The Committee determines the vesting period for the Company’s stock options. Generally, such stock options have vesting periods of immediate to four years. Certain option awards provide for accelerated vesting upon meeting specific retirement, death or disability criteria, and upon a change in control. During the nine month periods ended March 31, 2013 and 2012, the Company granted options to purchase 342,500 and 233,750 shares of the Company’s common stock, respectively.
In December 2012, the shareholders approved the 2012 Employee Equity Incentive Plan in the amount of 500,000 shares. This plan expires in 10 years and to date no shares have been issued from the plan. In addition, the shareholders approved the 2012 Non-Employee Director Stock Option Plan in the amount of 200,000 shares. This plan expires in 10 years and to date no shares have been issued from the plan.
Stock-based compensation expense for the nine month periods ended March 31, 2013 and 2012 was approximately $356,000 and $256,000, respectively. Compensation expense is recognized in the general and administrative expenses line item of the Company’s consolidated statements of operations on a straight-line basis over the vesting periods. As of March 31, 2013, there was approximately $1,339,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements to be recognized over a weighted-average period of 3.0 years.
Cash in the amount of $235,828 was received from the exercise of stock options for the nine month period ended March 31, 2013. No cash was received from the exercise of stock options for the nine month period ended March 31, 2012.
The fair values of the options granted during the periods ended March 31, 2013 and 2012 were estimated on the date of the grant using the Black-Scholes option-pricing model on the basis of the following weighted average assumptions during the respective periods:
| For the nine months ended | ||||||||
| March 31, | ||||||||
| 2013 | 2012 | |||||||
| Risk-free interest rate | 2.5 | % | 3.4 | % | ||||
| Expected option life in years | 6.5 | 6.5 | ||||||
| Expected stock price volatility | 75.1 | % | 75.4 | % | ||||
| Expected dividend yield | 0.0 | % | 0.0 | % | ||||
| Weighted-average fair value of options granted | $ | 2.94 | $ | 1.75 | ||||
The expected life was based on historical exercises and terminations. The expected volatility for the expected life of the options is determined using historical price changes of the Company’s stock over a period equal to that of the expected life of the options. The risk free rate is based upon the U.S. Treasury yield in effect at the time of the grant. The expected dividend yield is 0% as the Company has historically not declared dividends and does not expect to declare any in the future.
| 13 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
Changes in outstanding stock options during the nine months ended March 31, 2013 were as follows:
| Options | ||||||||||||||||
| Weighted | ||||||||||||||||
| Average | ||||||||||||||||
| Weighted | Remaining | |||||||||||||||
| Average | Contractual | Aggregate | ||||||||||||||
| Number of | Exercise | Life | Intrinsic | |||||||||||||
| Shares | Price ($) | (years) | Value (a) | |||||||||||||
| Outstanding as of June 30, 2012 | 1,820,930 | 3.60 | ||||||||||||||
| Granted | 342,500 | 3.73 | ||||||||||||||
| Exercised | (86,126 | ) | 2.74 | |||||||||||||
| Forfeited | (13,525 | ) | 2.02 | |||||||||||||
| Expired | (201,700 | ) | 5.10 | |||||||||||||
| Outstanding as of March 31, 2013 | 1,862,079 | 3.52 | 5.7 | $ | 4,553,976 | |||||||||||
| Exercisable and vested at March 31, 2013 | 1,169,655 | 3.87 | 3.9 | $ | 2,489,950 | |||||||||||
| Available for grant at March 31, 2013 | 802,475 | |||||||||||||||
| (a) | Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at March 31, 2013 or if exercised, the exercise dates, exceeds the exercise prices of the respective options. |
| 14 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
5.Income Taxes
For the three months ended March 31, 2013, the Company recorded an income tax benefit in continuing operations of $59,126. For the nine months ended March 31, 2013, the Company recorded an income tax benefit in continuing operations of $55,297.
For the nine months ended March 31, 2013 and March 31, 2012, the effective rate on continuing operations varied from the U.S. federal statutory rate primarily due to permanent book tax differences, state taxes, change in the valuation allowance and the impact of the intra-period tax allocation between continuing and discontinued operations.
The Company established a valuation against the deferred tax asset in prior years when management concluded that it is more likely than not that the deferred tax asset may not be fully realized. Management’s deferred tax asset assessment is unchanged as of March 31, 2013.
As of March 31, 2013 and June 30, 2012, the Company has no material unrecognized tax benefits and accrued interest and penalties.
6.Inventories
Inventories are summarized as follows:
| March 31, | June 30, | |||||||
| 2013 | 2012 | |||||||
| Raw material | $ | 2,183,479 | $ | 2,172,536 | ||||
| Work-in-process | 958,737 | 875,000 | ||||||
| Finished goods | 2,007,102 | 1,795,529 | ||||||
| 5,149,318 | 4,843,065 | |||||||
| Less valuation reserve | 700,918 | 462,224 | ||||||
| $ | 4,448,400 | $ | 4,380,841 | |||||
7.Accrued Expenses and Other Current Liabilities
The following summarizes accrued expenses and other current liabilities:
| March 31, | June 30, | |||||||
| 2013 | 2012 | |||||||
| Accrued payroll and vacation | $ | 436,352 | $ | 468,505 | ||||
| Accrued bonuses | 225,000 | 200,000 | ||||||
| Accrued commissions | 158,767 | 96,644 | ||||||
| Accrued professional and legal fees | 49,198 | 74,192 | ||||||
| Accrued royalties | 182 | 25,275 | ||||||
| Deferred income | 152,860 | 44,213 | ||||||
| Other | 180,923 | 166,103 | ||||||
| $ | 1,203,282 | $ | 1,074,932 | |||||
8.Commitments and Contingencies
The Company and its subsidiaries are from time to time involved in ordinary and routine litigation. Management presently believes that the ultimate outcome of these proceedings, individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, cash flows or result of operations. Nevertheless, litigation is subject to inherent uncertainties and unfavorable rulings could occur. An unfavorable ruling could include money damages and, in such event, could result in a material adverse impact on the Company’s results of operations in the period in which the ruling occurs.
| 15 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
9.Fair Value of Financial Instruments
We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of “observable inputs” and minimize the use of “unobservable inputs.” The three levels of inputs used to measure fair value are as follows:
Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.
Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.
The following is a summary of the carrying amounts and estimated fair values of our financial instruments at March 31, 2013 and June 30, 2012:
| March 31, 2013 | Carrying Amount | Fair Value | ||||||
| Cash and cash equivalents | $ | 6,091,564 | $ | 6,091,564 | ||||
| Trade accounts receivable | 2,788,281 | 2,788,281 | ||||||
| Trade accounts payable | 1,367,586 | 1,367,586 | ||||||
| June 30, 2012 | Carrying Amount | Fair Value | ||||||
| Cash and cash equivalents | $ | 6,273,015 | $ | 6,273,015 | ||||
| Trade accounts receivable | 3,158,084 | 3,158,084 | ||||||
| Trade accounts payable | 1,507,695 | 1,507,695 | ||||||
| Note receivable - short term | 198,117 | 198,117 | ||||||
The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:
Cash and cash equivalents
The carrying amount approximates fair value because of the short maturity of those instruments.
Trade Accounts Receivable
The carrying amount of trade receivables reflects net recovery value and approximates fair value because of their short outstanding terms.
Trade Accounts Payable
The carrying amount of trade payables approximates fair value because of their short outstanding terms.
Note Receivable
The carrying amount of the note receivable approximates fair value because the discount rate is fair market value.
Non-financial assets and liabilities
Certain non-financial assets and liabilities, principally goodwill, are measured at fair value on a non-recurring basis; that is the assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances, such as when evidence of impairment exists. At March 31, 2013 and for the nine months then ended, no fair value adjustments or material fair value measurements were required for non-financial assets or liabilities.
| 16 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
10.Goodwill and Intangible Assets
Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or product lines. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur and determination of our weighted-average cost of capital. We primarily use a discounted cash flow model in determining fair value, which consists of level three inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. There were no indicators that the recorded goodwill was impaired as of March 31, 2013 which required further testing.
The cost of acquiring or processing patents is capitalized. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $558,724 and $561,607 at March 31, 2013 and June 30, 2012, respectively. Accumulated amortization totaled $535,479 and $479,517 at March 31, 2013 and June 30, 2012, respectively. Amortization expense for the three month periods ended March 31, 2013 and March 31, 2012 was approximately $18,000. Amortization expense for the nine month periods ended March 31, 2013 and March 31, 2012 was approximately $53,000 and $41,000, respectively.
Net customer relationships reported in intangible and other assets totaled $400,000 and $520,000 at March 31, 2013 and June 30, 2012, respectively. Accumulated amortization amounted to $400,000 at March 31, 2013 and $280,000 at June 30, 2012, respectively. Amortization expense for the three month periods ended March 31, 2013 and March 31, 2012 was $40,000. Amortization expense for the nine month periods ended March 31, 2013 and March 31, 2012 was $120,000. Customer relationships are amortized on a straight-line basis over a five year period.
The following is a schedule of estimated future amortization expense as of March 31, 2013:
| Customer | ||||||||
| Patents | Relationships | |||||||
| 2013 | $ | 19,028 | $ | 40,000 | ||||
| 2014 | 74,093 | 160,000 | ||||||
| 2015 | 68,530 | 160,000 | ||||||
| 2016 | 65,468 | 40,000 | ||||||
| 2017 | 63,285 | - | ||||||
| Thereafter | 268,320 | - | ||||||
| $ | 558,724 | $ | 400,000 | |||||
11.Recent Accounting Pronouncements
In May 2011, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. Generally Accepted Accounting Principles (“GAAP”) and International Financial Reporting Standards (“IFRS”). This guidance amends U.S. GAAP to conform with measurement and disclosure requirements in IFRS. The amendments change the wording used to describe the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements, and they include those that clarify the FASB’s intent about the application of existing fair value measurement and disclosure requirements and those that change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. In addition, to improve consistency in application across jurisdictions, some changes in wording are necessary to ensure that U.S. GAAP and IFRS fair value measurement and disclosure requirements are described in the same way. This amended guidance is to be applied prospectively and is effective for fiscal years beginning after December 15, 2011. The adoption of the guidance did not have a material impact on the Company’s consolidated financial statements.
| 17 |
MISONIX, INC. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
In June 2011, the FASB amended Accounting Standard Codification 220, Comprehensive Income. The amendment eliminates the current option to report other comprehensive income and its components in the statement of changes in stockholders’ equity. In accordance with the amendment, an entity has the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income in one continuous statement or in two separate but consecutive statements. Additionally, reclassification adjustments from other comprehensive income to net income will be presented on the face of the financial statements. The amendment is effective for annual reporting periods beginning after December 15, 2011, which for us is July 1, 2012, with full retrospective application required. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
In September 2011, the FASB issued ASU No. 2011-08, Testing Goodwill for Impairment. Under the revised guidance, companies testing goodwill for impairment have the option of performing a qualitative assessment before calculating the fair value of the reporting unit (i.e., step 1 of the goodwill impairment test). If companies determine, on the basis of qualitative factors, that the fair value of the reporting unit is more likely than not less than the carrying amount, the two-step impairment test would be required. This update is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted. The Company is evaluating the revised guidance and does not anticipate that adoption will have a material impact on the Company’s consolidated financial statements.
| 18 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations of Misonix and its subsidiaries, in which we refer to the Company as “Misonix”, “we”, “our”, and “us”, should be read in conjunction with the accompanying unaudited financial statements included in “Item 1. Financial Statements” of this Report and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on September 20, 2012, for the fiscal year ended June 30, 2012 (“2012 Form 10-K”). Item 7 of the 2012 Form 10-K describes the application of our critical accounting policies, for which there have been no significant changes as of March 31, 2013.
Forward Looking Statements
This Report contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are intended to be covered by the safe harbors created thereby. Although the Company believes that the assumptions underlying the forward looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward looking statements contained in this Report will prove to be accurate. Factors that could cause actual results to differ from the results specifically discussed in the forward looking statements include, but are not limited to, the absence of anticipated contracts, higher than historical costs incurred in the performance of contracts or in conducting other activities, product mix in sales, future economic, competitive and market conditions, and the outcome of legal proceedings as well as management business decisions.
Nine months ended March 31, 2013 and 2012.
Net sales: Net sales increased $690,763 to $11,068,243 for the nine months ended March 31, 2013 from $10,377,480 for the nine months ended March 31, 2012. The increase in sales was primarily attributable to sales of the Company’s BoneScalpel and SonicOne products of $1,720,731 and $649,234, respectively, partially offset by lower Lysonix revenue of $750,820, lower NeuroAspirator revenue of $234,703 and lower Autosonix revenue of $724,115.
Set forth below are tables showing the Company’s net sales by (i) product category and (ii) geographic region for the nine months ended March 31, 2013 and 2012:
| Nine months ended March 31, | ||||||||||||
| 2013 | 2012 | Variance | ||||||||||
| BoneScalpel | $ | 4,831,205 | $ | 3,110,474 | $ | 1,720,731 | ||||||
| SonicOne | 1,427,209 | 777,885 | 649,324 | |||||||||
| SonaStar | 3,912,875 | 4,147,578 | (234,703 | ) | ||||||||
| Other | 896,954 | 2,341,543 | (1,444,589 | ) | ||||||||
| $ | 11,068,243 | $ | 10,377,480 | $ | 690,763 | |||||||
| Nine months ended March 31, | ||||||||
| 2013 | 2012 | |||||||
| United States | $ | 5,652,072 | $ | 5,690,301 | ||||
| Australia | 321,374 | 165,070 | ||||||
| Europe | 2,299,808 | 1,919,508 | ||||||
| Asia | 1,093,479 | 1,052,988 | ||||||
| Canada and Mexico | 436,738 | 346,316 | ||||||
| South America | 578,380 | 454,625 | ||||||
| South Africa | 363,429 | 253,250 | ||||||
| Middle East | 322,963 | 495,422 | ||||||
| $ | 11,068,243 | $ | 10,377,480 | |||||
| 19 |
Gross profit: Gross profit decreased to 55.2% for the nine months ended March 31, 2013 from 59.3% for the nine months ended March 31, 2012. The decrease is related to an unfavorable mix of high and low margin product deliveries in addition to the increase in minimum gross profit contribution requirement cost related to the Soma product, as a result of the Product License and Distribution Agreement with Puricore International Limited (“PuriCore”) dated July 19, 2011 (the “Distribution Agreement”), which had a 5% adverse effect on gross profit.
Selling expenses: Selling expenses increased $1,148,788 to $4,768,867 for the nine months ended March 31, 2013 from $3,620,079 for the nine months ended March 31, 2012. Selling expenses increased due to higher personnel costs of $707,364, primarily from an increase in headcount for customer service and support, higher commission expense of $156,078, higher travel expense of $120,731, higher advertising expenses of $50,507 and higher training, depreciation, freight costs and consulting expenses of $111,321.
General and administrative expenses: General and administrative expenses increased $16,437 to $3,290,671 for the nine months ended March 31, 2013 from $3,274,234 for the nine months ended March 31, 2012.
Research and development expenses: Research and development expenses increased $196,305 to $1,143,289 for the nine months ended March 31, 2013 from $946,984 for the nine months ended March 31, 2012. The increase is due to higher salary expenses of $121,557 and higher third party vendor product development costs of $76,370.
Other income (expense): Other income for the nine months ended March 31, 2013 was $1,713,415 as compared to $549,421 for the nine months ended March 31, 2012. The increase in other income is related to higher royalty income of $1,308,700, partially offset by higher royalty expense of $117,912. The increased royalty expense is due to a net fee recovery of $182,000 of BoneScalpel royalty expense for which we were not obligated to pay in the second quarter of fiscal 2012.
Income taxes: For the nine months ended March 31, 2013, the Company’s continuing operations effective tax rate was 4%, a tax benefit of $55,297, as compared to a benefit of 25% for the nine months ended March 31, 2012. The Company estimates its financial statement effective tax rate for the full year, inclusive of discontinued operations, to be approximately 1%. The actual effective rate for continuing operations may vary materially based on several factors including the realization of earn-outs recorded in discontinued operations and the related intraperiod tax allocation, the ratio of permanent differences to pretax income (loss), and a change in the valuation allowances as well as other factors.
| 20 |
Three months ended March 31, 2013 and 2012.
Net sales: Net sales decreased $586,259 to $3,023,487 for the three months ended March 31, 2013 from $3,609,746 for the three months ended March 31, 2012. The decrease in sales is primarily related to lower Lysonix revenue of $241,990, lower NeuroAspirator revenue of $233,467, lower BoneScalpel revenue of $126,579 and lower AutoSonic and Lithotripsy revenue of $169,287, partially offset by higher SonicOne revenue of $184,388.
Set forth below are tables showing the Company’s net sales by (i) product category and (ii) geographic region for the three months ended March 31, 2013 and 2012:
| Three months ended March 31, | ||||||||||||
| 2013 | 2012 | Variance | ||||||||||
| BoneScalpel | $ | 1,126,284 | $ | 1,252,863 | $ | (126,579 | ) | |||||
| SonicOne | 398,074 | 213,686 | 184,388 | |||||||||
| SonaStar | 1,286,779 | 1,520,246 | (233,467 | ) | ||||||||
| Other | 212,350 | 622,951 | (410,601 | ) | ||||||||
| $ | 3,023,487 | $ | 3,609,746 | $ | (586,259 | ) | ||||||
| Three months ended March 31, | ||||||||
| 2013 | 2012 | |||||||
| United States | $ | 1,566,912 | $ | 1,940,250 | ||||
| Australia | 39,700 | 84,244 | ||||||
| Europe | 579,509 | 445,504 | ||||||
| Asia | 309,696 | 569,302 | ||||||
| Canada and Mexico | 180,756 | 55,375 | ||||||
| South America | 171,992 | 174,886 | ||||||
| South Africa | 51,162 | 111,535 | ||||||
| Middle East | 123,760 | 228,650 | ||||||
| $ | 3,023,487 | $ | 3,609,746 | |||||
Gross profit: Gross profit decreased to 51.0% for the three months ended March 31, 2013 from 58.7% for the three months ended March 31, 2012. The decrease is related to unabsorbed factory costs due to lower sales volume, along with an unfavorable mix of low and high margin product deliveries in addition to the increase in minimum gross profit contribution requirement cost related to the Soma products as a result of the Distribution Agreement with Puricore dated July 19, 2011, which had a 6.2% adverse effect on gross profit.
Selling expenses: Selling expenses increased $518,936 to $1,764,718 for the three months ended March 31, 2013 from $1,245,782 for the three months ended March 31, 2012. Selling expenses increased due to higher personnel costs of $257,956, primarily from an increase in headcount for customer service and support, higher travel expenses of $94,206, higher commission expense of $60,109, higher advertising expenses of $38,578, higher depreciation expenses of $27,281 and higher training, clinical and consulting expenses of $42,416.
| 21 |
General and administrative expenses: General and administrative expenses increased $131,584 to $1,155,613 for the three months ended March 31, 2013 from $1,024,029 for the three months ended March 31, 2012. The increase is primarily related to higher non-cash stock based compensation expense of $48,898 and higher stockholder relations expense of $19,870.
Research and development expenses: Research and development expenses increased $46,593 to $379,901 for the three months ended March 31, 2013 from $333,308 for the three months ended March 31, 2012. The increase is primarily due to higher personnel costs of $32,201.
Other income (expense): Other income for the three months ended March 31, 2013 was $999,611 as compared to $122,322 for the three months ended March 31, 2012. The increase in other income is related to higher royalty income of $889,359.
Income taxes: For the three months ended March 31, 2013, the Company recorded an effective tax rate of 8%, a benefit of $59,126, as compared to a benefit of $85,862, or 24%, for the three months ended March 31, 2012. The Company estimates its financial statement effective tax rate for the full year, inconclusive of discontinued operations to be approximately 1%. The actual effective rate for continuing operations may vary materially based on several factors including the realization of earn-outs recorded in discontinued operations and the related intraperiod tax allocation, the ratio of permanent differences to pretax income (loss), and a change in the valuation allowances as well as other factors.
Discontinued Operations
See Note 1 of the notes to consolidated financial statements included in Part I, Item 1 of this Report for a description of the discontinued operations. The following summarizes the results of the discontinued operations:
| For the three months ended | For the nine months ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenues | $ | 4,975 | $ | 28,588 | $ | 14,925 | $ | 1,455,791 | ||||||||
| Income/(loss) from discontinued operations, before tax | $ | 4,975 | $ | (214,313 | ) | $ | 14,768 | $ | (551,011 | ) | ||||||
| Gain on sale of discontinued operations | 250,000 | 254,788 | 250,000 | 1,705,414 | ||||||||||||
| Income tax expense | (82,968 | ) | 21,314 | (82,968 | ) | (380,437 | ) | |||||||||
| Net income from discontinued operations net of tax | $ | 172,007 | $ | 61,789 | $ | 181,800 | $ | 773,966 | ||||||||
Liquidity and Capital Resources
We regularly review our cash funding requirements and attempt to meet those requirements through a combination of cash on hand, cash provided by operations and possible future public or private debt and/or equity offerings. At times, we evaluate possible acquisitions of, or investments in, businesses that are complementary to ours, which may require the use of cash. We believe that our cash, other liquid assets and access to equity capital markets, taken together, provide adequate resources to fund ongoing operating expenditures. In the event that they do not, we may require additional funds in the future to support our working capital requirements or for other purposes and may seek to raise such additional funds through the sale of public or private equity and/or debt financings, and divestiture of current business lines as well as from other sources. No assurance can be given that additional financing will be available in the future or that if available, such financing will be obtainable on favorable terms when required.
Working capital at March 31, 2013 and June 30, 2012 was $11,086,000 and $11,734,000, respectively. For the nine months ended March 31, 2013, cash provided by operations totaled $131,235, primarily due to lower inventory of $130,558. For the nine months ended March 31, 2013, cash used in investing activities totaled $730,314, primarily due to Company owned placed units. For the nine months ended March 31, 2013, cash provided by financing activities was $235,828 from the exercise of stock options.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to the Company.
Other
In the opinion of management, inflation has not had a material effect on the operations of the Company.
| 22 |
New Accounting Pronouncements
We are required to adopt certain new accounting pronouncements. See note 11 to our consolidated financial statements included herein.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Market Risk:
The principal market risks (i.e., the risk of loss arising from adverse changes in market rates and prices) to which the Company is exposed are interest rates on short-term investments.
Interest Rate Risk:
The Company earns interest on cash balances and pays interest on debt incurred. In light of the Company’s existing cash, results of operations and projected borrowing requirements, the Company does not believe that a 10% change in interest rates would have a significant impact on its consolidated financial position.
| 23 |
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decision regarding required disclosures. The Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of March 31, 2013 and, based on their evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
There has been no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the nine months ended March 31, 2013 that has materially affected, or is reasonable likely to materially affect, the Company’s internal control over financial reporting.
| 24 |
Part II - OTHER INFORMATION
Item 1A. Risk Factors.
Risks and uncertainties that, if they were to occur, could materially adversely affect our business or that could cause our actual results to differ materially from the results contemplated by the forward-looking statements contained in this Report and other public statements were set forth in the “Item 1A. Risk Factors” section of our 2012 Form 10-K. There have been no material changes from the risk factors disclosed in that Form 10-K.
Item 6. Exhibits.
| Exhibit 31.1- | Rule 13a-14(a)/15d-14(a) Certification |
| Exhibit 31.2- | Rule 13a-14(a)/15d-14(a) Certification |
| Exhibit 32.1- | Section 1350 Certification of Chief Executive Officer |
| Exhibit 32.2- | Section 1350 Certification of Chief Financial Officer |
| 25 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 9, 2013
| MISONIX, INC. | ||
| (Registrant) | ||
| By: | /s/ Michael A. McManus, Jr. | |
| Michael A. McManus, Jr. | ||
| President and Chief Executive Officer | ||
| By: | /s/ Richard Zaremba | |
| Richard Zaremba | ||
| Senior Vice President, Chief Financial Officer, | ||
| Treasurer and Secretary | ||
| 26 |